Bioxytran's (OTCQB: BIXT) antiviral compound PHM23 has been selected for inclusion in the University of Georgia's grant submission to the USDA's $100 million HPAI Poultry Innovation Grand Challenge. The selection highlights PHM23's potential to combat Bird Flu (H5N1) through its galectin antagonist mechanism. The drug works by blocking viral spike proteins from attaching to host cells, demonstrating broad-spectrum antiviral activity in in vitro studies. This recognition from a leading poultry health institution validates Bioxytran's technology platform and positions PHM23 as a promising solution for addressing viral threats in the poultry industry, which faces billions in annual losses due to H5N1 outbreaks.
Il composto antivirale PHM23 di Bioxytran (OTCQB: BIXT) è stato selezionato per essere incluso nella proposta di finanziamento dell'Università della Georgia per la sfida innovativa USDA da 100 milioni di dollari sull'influenza aviaria ad alta patogenicità (HPAI). Questa scelta evidenzia il potenziale di PHM23 nel contrastare l'influenza aviaria (H5N1) grazie al suo meccanismo di antagonista della galectina. Il farmaco agisce impedendo alle proteine spike virali di legarsi alle cellule ospiti, dimostrando un'attività antivirale ad ampio spettro in studi in vitro. Questo riconoscimento da parte di un'importante istituzione per la salute avicola conferma la validità della piattaforma tecnologica di Bioxytran e posiziona PHM23 come una soluzione promettente per affrontare le minacce virali nel settore avicolo, che ogni anno subisce perdite miliardarie a causa delle epidemie di H5N1.
El compuesto antiviral PHM23 de Bioxytran (OTCQB: BIXT) ha sido seleccionado para su inclusión en la propuesta de subvención de la Universidad de Georgia para el Desafío de Innovación Avícola HPAI del USDA de 100 millones de dólares. Esta selección destaca el potencial de PHM23 para combatir la gripe aviar (H5N1) mediante su mecanismo antagonista de galectina. El fármaco actúa bloqueando la unión de las proteínas espiga virales a las células huésped, demostrando una actividad antiviral de amplio espectro en estudios in vitro. Este reconocimiento por parte de una institución líder en salud avícola valida la plataforma tecnológica de Bioxytran y posiciona a PHM23 como una solución prometedora para enfrentar las amenazas virales en la industria avícola, que enfrenta pérdidas anuales de miles de millones debido a los brotes de H5N1.
Bioxytran(OTCQB: BIXT)의 항바이러스 화합물 PHM23이 조지아 대학교의 미국 농무부(USDA)의 1억 달러 규모 고병원성 조류인플루엔자(HPAI) 가금류 혁신 챌린지 지원 과제에 선정되었습니다. 이번 선정은 갈렉틴 길항제 메커니즘을 통해 조류 인플루엔자(H5N1)를 방어할 수 있는 PHM23의 잠재력을 부각합니다. 이 약물은 바이러스 스파이크 단백질이 숙주 세포에 부착되는 것을 차단하며, 시험관 내 연구에서 광범위한 항바이러스 활성을 보여주었습니다. 가금류 건강 분야의 선도 기관으로부터 인정받은 이번 성과는 Bioxytran의 기술 플랫폼을 입증하며, H5N1 발생으로 매년 수십억 달러의 손실을 겪는 가금류 산업의 바이러스 위협 대응에 PHM23이 유망한 해결책임을 보여줍니다.
Le composé antiviral PHM23 de Bioxytran (OTCQB : BIXT) a été sélectionné pour être inclus dans la demande de subvention de l'Université de Géorgie pour le USDA HPAI Poultry Innovation Grand Challenge de 100 millions de dollars. Cette sélection met en lumière le potentiel de PHM23 à combattre la grippe aviaire (H5N1) grâce à son mécanisme antagoniste de la galectine. Le médicament agit en bloquant l'attachement des protéines de pointe virales aux cellules hôtes, démontrant une activité antivirale à large spectre lors d'études in vitro. Cette reconnaissance par une institution de premier plan dans la santé avicole valide la plateforme technologique de Bioxytran et positionne PHM23 comme une solution prometteuse pour faire face aux menaces virales dans l'industrie avicole, qui subit chaque année des pertes de plusieurs milliards dues aux épidémies de H5N1.
Die antivirale Verbindung PHM23 von Bioxytran (OTCQB: BIXT) wurde für die Aufnahme in den Förderantrag der University of Georgia für die USDA HPAI Poultry Innovation Grand Challenge im Wert von 100 Millionen US-Dollar ausgewählt. Die Auswahl unterstreicht das Potenzial von PHM23, die Vogelgrippe (H5N1) durch seinen Galektin-Antagonisten-Mechanismus zu bekämpfen. Das Medikament wirkt, indem es virale Spike-Proteine daran hindert, sich an Wirtszellen zu binden, und zeigt in In-vitro-Studien eine breitgefächerte antivirale Aktivität. Diese Anerkennung durch eine führende Institution im Bereich Geflügelgesundheit bestätigt die Technologieplattform von Bioxytran und positioniert PHM23 als vielversprechende Lösung zur Bekämpfung viraler Bedrohungen in der Geflügelindustrie, die jährlich Milliardenverluste durch H5N1-Ausbrüche erleidet.
Positive
Selection by University of Georgia, a world leader in poultry health, validates PHM23's potential
Inclusion in $100M USDA grant submission increases visibility and credibility
PHM23's mechanism minimizes risk of viral mutations
Technology could help prevent billions in annual losses to poultry industry
Negative
PHM23 efficacy only demonstrated in in vitro studies so far
No guarantee of winning the USDA grant or receiving funding
Still seeking partnerships for development and deployment
PHM23 was one of a handful of molecules chosen by the university
Bird Flu helping PHM23 gain awareness of broad-spectrum activity at a university level
BOSTON, MASSACHUSETTS, May 21, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing breakthrough antiviral treatments, announced that the University of Georgia confirmed the antiviral PHM23 was to be included amongst other drug candidates in the Universities grant submission to the U.S. Department of Agriculture’s (USDA) $100 million Highly Pathogenic Avian Influenza (HPAI) Poultry Innovation Grand Challenge. This prestigious recognition highlights PHM23’s potential as a groundbreaking solution to combat Bird Flu (H5N1) and underscores its broad-spectrum antiviral activity.
The University of Georgia is a world leader in poultry health. The selection of this molecule demonstrates how PHM23 stands out in the antiviral space as a promising therapeutic candidate capable of neutralizing viral infections. Inclusion in this high-profile submission is expected to amplify awareness of the antiviral activity of Bioxytran’s molecule. By targeting galectins—proteins critical to viral replication—PHM23 has demonstrated effectiveness against viruses similar to Bird Flu in in vitro studies, positioning it as an antiviral candidate for addressing multiple viral threats.
“This recognition from the University of Georgia is a testament to the transformative potential of complex carbohydrate based antiviral drugs in addressing one of the most pressing challenges in global agriculture,” said David Platt, CEO of Bioxytran, Inc. “Being selected for the USDA’s HPAI Poultry Innovation Grand Challenge submission validates our innovative galectin antagonist platform and highlights PHM23’s role in safeguarding animal health and the global food supply. We are excited to collaborate with leading academic institutions to advance this breakthrough therapy.”
Bioxytran’s galectin antagonist technology, embodied in PHM23, works by blocking viral spike proteins from attaching to host cells, a mechanism conserved across mammals that minimizes the risk of viral mutations. This approach offers hope for rapid containment of H5N1 outbreaks, potentially eliminating the need for mass culling and mitigating billions in annual losses to the poultry industry.
The USDA’s HPAI Poultry Innovation Grand Challenge, with up to $100 million in funding, aims to curb the spread of Bird Flu, protect U.S. poultry farmers, and ensure food security. Bioxytran is actively seeking partnerships with academic, industry, and government stakeholders to accelerate PHM23’s development and deployment in response to this urgent global need.
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over 90%. For more information, visit www.bioxytraninc.com
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What is PHM23 and how does it work against Bird Flu?
PHM23 is Bioxytran's antiviral compound that works by blocking viral spike proteins from attaching to host cells through a galectin antagonist mechanism, showing potential effectiveness against Bird Flu (H5N1) in in vitro studies.
Why is BIXT stock's inclusion in University of Georgia's USDA grant submission significant?
The inclusion validates PHM23's potential as an antiviral treatment, as UGA is a world leader in poultry health, and the submission is for a prestigious $100M USDA HPAI Poultry Innovation Grand Challenge.
What stage of development is Bioxytran's PHM23 currently in?
PHM23 has shown effectiveness in in vitro studies and is currently seeking partnerships for further development and deployment.
How could PHM23 benefit the poultry industry?
PHM23 could help prevent billions in annual losses by potentially eliminating the need for mass culling during H5N1 outbreaks and protecting poultry farms from Bird Flu.
What is the potential market impact for BIXT's antiviral treatment?
The treatment addresses a significant market need in the poultry industry, which faces billions in annual losses from Bird Flu, with potential support from a $100M USDA innovation challenge.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
